Amina Ahmed, MD; Paula Anastasia, RN, MN, AOCN; and Ali McBride, PharmD, MS, provide their support for the use of PARP inhibitors as maintenance therapy in ovarian cancer, and that the optimization of this therapy requires further research to discover the best therapeutic combinations that will be personalized based on patient characteristics.
An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
UCLA Health
Los Angeles, CA
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
The University of Arizona Cancer Center
Tucson, AZ
Get TOP in Your Inbox
Stay up to date with the latest oncology pharmacy news and insights by subscribing to our e-newsletter!